Sagardui, who spoke in the session addressing the global viral vector shortage on day one of the conference, explained how her administration supported Viralgen, a producer of recombinant adeno-associated virus vectors based in San Sebastian, from the early days.

"We have a long tradition of working with the industry in the Basque Country," she said. "We were looking for research and innovation projects in healthcare not only to improve health in our country but also our economy. [Viralgen] was really an opportunity for us, and so we started sharing their project from the early stage."

Viralgen's Pro10 suspension manufacturing platform enables customers to benefit from industry-leading scalability, reproducibility, and speed to market.

Click on the video below to learn more.

Cevec Pharmaceuticals CEO stresses challenges in producing AAV vectors
It will be a real challenge to produce sufficient quantities of gene therapy products, in particular when it comes to adeno-associated virus (AAV) vectors,...

Meeting on the Med opens with new data and eyes on the money
BARCELONA, SPAIN -- The Cell & Gene Meeting on the Med conference kicked off on April 20 as speakers assessed the current state of the cell and gene therapy...